CStone Pharmaceuticals
CStone Pharmaceuticals's GHG Emissions Data Preview
In 2023, CStone Pharmaceuticals completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), and Scope 2 (indirect emissions from purchased energy).
However, CStone Pharmaceuticals has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
| Metric (tCO2e) | 2024 | 2023 | 2022 | 2021 - 2017 |
|---|---|---|---|---|
Total Scope 1 | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 2 | ||||
Unspecified Calculation Method | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
Total Scope 3 | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data. | 0000000 |
This table provides a simplified preview of selected GHG emissions data points. To access the complete dataset with full disclosures, detailed breakdowns, and source traceability, create a free account to view purchase options.
Insights into CStone Pharmaceuticals's Operational Emissions
In 2023, the total operational greenhouse gas (GHG) emissions of CStone Pharmaceuticals amounted to 446.63 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).
Compared to 2022, the total operational greenhouse gas (GHG) emissions of CStone Pharmaceuticals decreased by 11.79%, showing that the company has made progress in taking action to reduce the climate impact of its operations.
CStone Pharmaceuticals's Scope 1 Emissions Over Time
- Total Scope 1
- Year-over-Year Change
What are CStone Pharmaceuticals's Scope 1 emissions?
In 2023, the total Scope 1 emissions of CStone Pharmaceuticals were 0 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).
What are CStone Pharmaceuticals's Scope 2 emissions?
In 2023, CStone Pharmaceuticals reported Scope 2 greenhouse gas (GHG) emissions of 446.63 tCOâ‚‚e without specifying the calculation method.
Has CStone Pharmaceuticals reduced its Scope 2 emissions over time?
Since 2020, CStone Pharmaceuticals's Scope 2 greenhouse gas (GHG) emissions (Unspecified Calculation Method) have remained relatively stable, indicating that CStone Pharmaceuticals 's emissions have plateaued with no significant change in its energy consumption footprint.
Compared to the previous year (2022), CStone Pharmaceuticals's Scope 2 emissions (Unspecified Calculation Method) fell by 11.79% in 2023, showing that the company has made progress in taking action to reduce the climate impact of its energy consumption.
What methodology does CStone Pharmaceuticals use for Scope 2 reporting?
In 2023, CStone Pharmaceuticals reported its Scope 2 emissions using an unspecified methodology.
CStone Pharmaceuticals's Scope 2 Emissions Over Time
- Total Scope 2 (Unspecified Calculation Method)
Insights into CStone Pharmaceuticals's Total Carbon Footprint
In 2023, CStone Pharmaceuticals reported a total carbon footprint of 446.63 metric tons of COâ‚‚ equivalent (tCOâ‚‚e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 11.79% decrease compared to 2022, indicating progress in reducing its overall greenhouse gas output.